Cara Therapeutics (Germany) Buy Hold or Sell Recommendation
| 69C Stock | EUR 4.84 0.00 0.00% |
Assuming the 90 days horizon and your above-average risk tolerance, our recommendation regarding Cara Therapeutics is 'Strong Sell'. Macroaxis provides Cara Therapeutics buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding 69C positions.
Check out Cara Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. Note, we conduct extensive research on individual companies such as Cara and provide practical buy, sell, or hold advice based on investors' constraints. Cara Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
Cara |
Execute Cara Therapeutics Buy or Sell Advice
The Cara recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Cara Therapeutics. Macroaxis does not own or have any residual interests in Cara Therapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Cara Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Good | Details | |
Volatility | Dangerous | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Moves slightly opposite to the market | Details | |
Analyst Consensus | Not Available | Details | |
Reporting Quality (M-Score) | Inapplicable | Details |
Cara Therapeutics Trading Alerts and Improvement Suggestions
| Cara Therapeutics is way too risky over 90 days horizon | |
| Cara Therapeutics appears to be risky and price may revert if volatility continues | |
| The company reported the revenue of 23.03 M. Net Loss for the year was (88.44 M) with loss before overhead, payroll, taxes, and interest of (59.67 M). | |
| Cara Therapeutics has accumulated about 134.45 M in cash with (60.09 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.38. | |
| Roughly 66.0% of the company shares are owned by institutions such as pension funds |
Cara Therapeutics current analysts advice
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Cara analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Cara analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
The consensus estimates and target price estimation comprises individual analyst assessments, and may or may not mutch the Macroaxis buy or sell advice. It is determined by taking an average of all analyst recommendations and classifying them as Strong Buy, Buy, Hold, or Sell.
Cara Therapeutics Returns Distribution Density
The distribution of Cara Therapeutics' historical returns is an attempt to chart the uncertainty of Cara Therapeutics' future price movements. The chart of the probability distribution of Cara Therapeutics daily returns describes the distribution of returns around its average expected value. We use Cara Therapeutics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Cara Therapeutics returns is essential to provide solid investment advice for Cara Therapeutics.
| Mean Return | 1.39 | Value At Risk | -10.64 | Potential Upside | 15.13 | Standard Deviation | 10.23 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Cara Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Cara Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Cara Therapeutics or Healthcare sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Cara Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Cara stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 1.40 | |
β | Beta against Dow Jones | -0.68 | |
σ | Overall volatility | 10.62 | |
Ir | Information ratio | 0.13 |
Cara Therapeutics Volatility Alert
Cara Therapeutics is displaying above-average volatility over the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Cara Therapeutics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Cara Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Cara Therapeutics Fundamentals Vs Peers
Comparing Cara Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Cara Therapeutics' direct or indirect competition across all of the common fundamentals between Cara Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Cara Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Cara Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Cara Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Cara Therapeutics to competition |
| Fundamentals | Cara Therapeutics | Peer Average |
| Return On Equity | -0.45 | -0.31 |
| Return On Asset | -0.26 | -0.14 |
| Profit Margin | (2.25) % | (1.27) % |
| Operating Margin | (2.28) % | (5.51) % |
| Current Valuation | 450.58 M | 16.62 B |
| Shares Outstanding | 53.73 M | 571.82 M |
| Shares Owned By Insiders | 16.10 % | 10.09 % |
| Shares Owned By Institutions | 65.69 % | 39.21 % |
| Price To Book | 3.33 X | 9.51 X |
| Price To Sales | 14.36 X | 11.42 X |
| Revenue | 23.03 M | 9.43 B |
| Gross Profit | (59.67 M) | 27.38 B |
| EBITDA | (88.83 M) | 3.9 B |
| Net Income | (88.44 M) | 570.98 M |
| Cash And Equivalents | 134.45 M | 2.7 B |
| Cash Per Share | 3.38 X | 5.01 X |
| Total Debt | 4.99 M | 5.32 B |
| Debt To Equity | 4.30 % | 48.70 % |
| Current Ratio | 3.40 X | 2.16 X |
| Book Value Per Share | 3.44 X | 1.93 K |
| Cash Flow From Operations | (60.09 M) | 971.22 M |
| Earnings Per Share | (1.50) X | 3.12 X |
| Target Price | 26.33 | |
| Number Of Employees | 84 | 18.84 K |
| Beta | 0.96 | -0.15 |
| Market Capitalization | 508.24 M | 19.03 B |
| Total Asset | 247.06 M | 29.47 B |
| Z Score | 60.6 | 8.72 |
| Net Asset | 247.06 M |
Cara Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Cara . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Cara Therapeutics Buy or Sell Advice
When is the right time to buy or sell Cara Therapeutics? Buying financial instruments such as Cara Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Cara Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Computers Thematic Idea Now
Computers
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Computers theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Computers Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Cara Stock
Cara Therapeutics financial ratios help investors to determine whether Cara Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Cara with respect to the benefits of owning Cara Therapeutics security.